Press Releases
Follow-up to questioning about Fed Gov Brainard’s affiliation with Clinton campaign
WASHINGTON, D.C. – Rep.
WASHINGTON, D.C. – Rep. Scott Garrett (NJ-05) issued the following statement after the U.S. Court of Appeals for the D.C. Circuit ruled that the structure of the Consumer Financial Protection Bureau (CFPB) is unconstitutional:
WASHINGTON, D.C. – Rep. Scott Garrett (NJ-05) issued the following statement on the passing of Israeli President Shimon Peres:
WASHINGTON, D.C. – Rep. Scott Garrett (NJ-05) issued the following statement after voting for H.R. 5931, the Prohibiting Future Ransom Payments to Iran Act, to make sure the United States never pays ransom to Iran ever again. Garrett is a co-sponsor of this legislation:
WASHINGTON, D.C. – Capital Markets and Government-Sponsored Enterprises Subcommittee Chairman Scott Garrett (NJ-05) delivered the following remarks at a hearing entitled, “Examining the Agenda of Regulators SROs, and Standard-Setters for Accounting, Auditing, and Municipal Securities”:
WASHINGTON, D.C. – Rep. Scott Garrett, (NJ-05) Chairman of the subcommittee on Capital Markets and Government-Sponsored Enterprises, delivered the following opening remarks at Financial Services Committee hearing entitled, “The Annual Report of the Financial Stability Oversight Council” featuring Treasury Secretary Jack Lew:
WASHINGTON, D.C. – Rep. Scott Garrett (NJ-05) issued the following statement after the House passed H.R. 5859, the Community Counterterrorism Preparedness Act, a bill that Garrett co-sponsored and supported:
WASHINGTON, D.C. – Capital Markets and Government-Sponsored Enterprises Subcommittee Chairman Scott Garrett (NJ-05) delivered the following remarks at a hearing entitled, “Corporate Governance: Fostering a System that Promotes Capital Formation and Maximizes Shareholder Value”:
WASHINGTON, D.C. – Rep. Scott Garrett (NJ-05) issued the following statement after the Food and Drug Administration (FDA) this week announced the accelerated approval for a new treatment for Duchenne muscular dystrophy:
WASHINGTON, D.C. – Rep. Scott Garrett (NJ-05) called on the Food and Drug Administration (FDA) to express concerns over the near monopoly currently held by Mylan Pharmaceuticals on the EpiPen (epinephrine injection) which is used in the treatment of severe allergic reactions.
- 1 of 50
- next ›